Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disease progression is main barrier to allogeneic hematopoietic stem cell transplantation (HCT) in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Preston, E. V.; Chinapen, S.; Borrill, T.; Davis, E.; Shaffer, B. C.; Tamari, R.; Jakubowski, A. A.; Perales, M. A.; Ponce, D. M.; Shah, G. L.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Widespread use of measurable residual disease in acute myeloid leukemia practice
    Journal Article

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Estey, E.; Tallman, M. S.
    Leukemia Research (2018)

    Fulltext@MSK | Save
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
    Journal Article

    Stein, E. M.; Walter, R. B.; Erba, H. P.; Fathi, A. T.; Advani, A. S.; Lancet, J. E.; Ravandi, F.; Kovacsovics, T.; DeAngelo, D. J.; Bixby, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Journal Article

    Stein, E. M.
    Future Oncology (2018)

    Fulltext@MSK | Save
  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; Dinardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I.; Kantarjian, H. M.; Collins, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)
    Meeting Abstract

    Fathi, A. T.; Dinardo, C. D.; Kline, I.; Kenvin, L.; Gupta, I.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Meeting Abstract

    Cook, R. J.; Stein, E.; Steensma, D. P.; Sekeres, M. A.; Bixby, D. L.; Rizzieri, D.; Jurcic, J. G.; Vigil, C. E.; Redner, R.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Targeted differentiation therapy with mutant IDH inhibitors: Early experiences and parallels with other differentiation agents
    Journal Article

    Stein, E.; Yen, K.
    Annual Review of Cancer Biology (2017)

    Fulltext@MSK | Save
  • Spliceosomal dysfunction Is a critical mediator of IDH2 mutant leukemogenesis
    Meeting Abstract

    Yoshimi, A.; Lin, K. T.; Wiseman, D.; Intlekofer, A. M.; Wang, B.; Pastore, A.; Rahman, M.; Lee, S. C. W.; Liu, B.; Micol, J. B.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genetic profiling and deep IDH1 mutation clearance to ≤0.04% in ivosidenib (AG-120)-treated patients with mutant IDH1 relapsed or refractory and untreated AML
    Meeting Abstract

    Stone, R. M.; Choe, S.; Zhang, V.; Marteyn, B.; Penard-Lacronique, V.; Wang, H.; DiNardo, C. D.; Stein, E. M.; Fathi, A. T.; Tallman, M. S.; more...
    Blood (2017)

    Fulltext@MSK | Save